Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06821191
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
78 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Artery Disease
RECRUITING
NCT07497386
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
150 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Unresectable Locally Recurrent Breast Cancer


Unresectable Locally Metastatic Breast Cancer
ACTIVE_NOT_RECRUITING
NCT06048718
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
28 Enrollment(s)
13 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer


Metastatic Breast Cancer
NOT_YET_RECRUITING
NCT07574320
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome
76 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
IBS-D (Diarrhea-predominant)
ACTIVE_NOT_RECRUITING
NCT06172127
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
165 Enrollment(s)
36 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-positive Breast Cancer
COMPLETED
NCT02193971
Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)
3,429 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Acute Coronary Syndrome
RECRUITING
NCT06928818
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
100 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Cancer of Breast


Trastuzumab Emtansine


Trastuzumab Deruxtecan
ACTIVE_NOT_RECRUITING
NCT06731803
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
36 Enrollment(s)
15 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Esophagogastric Adenocarcinoma